Cadrenal Therapeutics, Inc. (CVKD) Tops Q2 EPS by 27c

Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) reported Q2 EPS of ($1.14), $0.27 better than the analyst estimate of ($1.41).

For earnings history and earnings-related data on Cadrenal Therapeutics, Inc. (CVKD) click here.

You May Also Be Interested In

• TD Cowen Starts Braveheart Bio (BRVE) at Buy
• GitLab Inc (GTLB) PT Raised to $50 at Cantor Fitzgerald
• Mizuho Downgrades PG&E Corporation (PCG) to Neutral